OUR STRATEGY

Our pivotal strategy is identification of early market entry opportunities in immuno-oncotherapeutics and development of a product pipeline up to pre-clinical stage. Through collaborative early stage partnerships, Zumutor enables usage of our platforms to take a new mAb from sequence to scale.

Our biosimilar strategy involves out-licensing molecules to marketing partners for specific geographies. The model is turnkey partnership /solution/system beginning with early stage development, preclinical and clinical trials, and regulatory submissions enabling the partner to retain all newly generated IP.

OUR BUSINESS MODEL

Product and process development, licensee
– manufacture along with market
and outsourced animal toxicity studies
and clinical trials serve partners in
production of high-quality bio therapeutics.

In-house development of new
biologics for ultimate enterprise
value

PARTNERED INNOVATION ENGINE

  

 

  • Through early stage partnerships, Zumutor enables usage of
    protein display platforms. This involves a collaborative approach through development and potential market reach.
  • Licensing of biosimilars for time to market

COLLABORATIONS

Zumutor also collaborates closely with several key members of academia such as 

Prof. Balaji Rao
Chairman, MBU
Indian Institute of Science

Logo_ Picture 3


Prof. Balaji Rao
Chemical & Biomolecular
engineering
NCSU, Raleigh

Logo_ Picture 3


Prof. Raghavan V
Chemical Engineering
Indian Institute of
Technology, Delhi

Logo_Picture 2(1)


Prof. Raghavan V
Bioinformatics & Structure
IISER, Pune

Logo_ Picture 4